Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Tong, Dan ^a   Heinze, Georg ^a   Pils, Dietmar ^a   Wolf, Andrea ^a   Singer, Christian F ^a   Concin, Nicole ^b   Hofstetter, Gerda ^b   Schiebel, Ingrid ^a   Rudas, Margaretha ^a   Zeillinger, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL MEMBRANE PROTEIN 1; EPITHELIAL MEMBRANE PROTEIN 2; EPITHELIAL MEMBRANE PROTEIN 3; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; PERIPHERAL MYELIN PROTEIN 22; UNCLASSIFIED DRUG; MYELIN PROTEIN; PMP22 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; AUSTRIA; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LUNG CARCINOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TIME;

AUSTRIA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYELIN PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650037004     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-682     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Lønning PE. Breast cancer prognostication and prediction: are we making progress?. Ann Oncol 2007, 18(Suppl 8):viii3-7.
3. Evtimova V, Zeillinger R, Weidle UH. Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. Tumour Biol 2003, 24:189-198. 10.1159/000074429, 14654713.
4. Jetten AM, Suter U. The peripheral myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acid Res Mol Biol 2000, 64:97-129. full_text, 10697408.
5. Kury FD, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Zeillinger R, Spona J. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. Oncogene 1990, 5:1403-1408.
6. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer 2008, 8:339-. 10.1186/1471-2407-8-339, 2631011, 19025599.
7. Schemper M, Smith TA. Note on Quantifying Follow-up in Studies of Failure Time. Controll Clin Trials 1996, 17:343-346.
8. Grambsch PM, Therneau T. Proportional Hazards Tests and Diagnostics based on Weighted Residuals. Biometrika 1994, 81:515-526.
9. Schemper M, Henderson R. Predictive Accuracy and Explained Variation in Cox Regression. Biometrics 2000, 56:249-255. 10.1111/j.0006-341X.2000.00249.x, 10783803.
10. Heinze G, Schemper M. Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 2003, 71:155-163. 10.1016/S0169-2607(02)00077-9, 12758137.
11. Harrell FE. Resampling: Validating, Describing, and Simplifying the Model. Regression Modeling Strategies 2001, 93-94. New York: Springer New York, Harrell FE Jr.
12. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 1999, 56:91-97. 10.1023/A:1006262501062, 10517346.
13. Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer 2007, 43:745-751. 10.1016/j.ejca.2006.11.018, 17257824.
14. Douglas DS, Popko B. Mouse forward genetics in the study of the peripheral nervous system and human peripheral neuropathy. Neurochem Res 2009, 34:124-137. 10.1007/s11064-008-9719-4, 2759972, 18481175.
15. Li J, Kleeff J, Esposito I, Kayed H, Felix K, Giese T, Büchler MW, Friess H. Expression analysis of PMP22/Gas3 in premalignant and malignant pancreatic lesions. J Histochem Cytochem 2005, 53:885-893. 10.1369/jhc.4A6546.2005, 15995147.
16. Hühne K, Park O, Liehr T, Rautenstrauss B. Expression analysis of the PMP22 gene in glioma and osteogenic sarcoma cell lines. J Neurosci Res 1999, 58:624-631.
17. van Dartel M, Leenstra S, Troost D, Hulsebos TJ. Infrequent but high-level amplification of 17p11.2 approximately p12 in human glioma. Cancer Genet Cytogenet 2003, 140:162-166. 10.1016/S0165-4608(02)00683-0, 12645656.